- Home
- SGMO vs BDTX Comparison
SGMO vs BDTX Comparison
Compare SGMO & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGMO | BDTX |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.2M | 116.8M |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SGMO | BDTX |
|---|---|---|
| Price | $0.33 | $2.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $7.00 | ★ $10.20 |
| AVG Volume (30 Days) | ★ 4.5M | 607.9K |
| Earning Date | 05-11-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 66.89 | ★ 130.71 |
| EPS | N/A | ★ 0.39 |
| Revenue | ★ $36,567,000.00 | N/A |
| Revenue This Year | $4.79 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.35 |
| Revenue Growth | ★ 88.60 | N/A |
| 52 Week Low | $0.32 | $1.20 |
| 52 Week High | $0.88 | $4.94 |
Technical Indicators
Market Signals| Indicator | SGMO | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.95 | 43.75 |
| Support Level | N/A | $1.93 |
| Resistance Level | $0.56 | $2.86 |
| Average True Range (ATR) | 0.03 | 0.14 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 15.03 | 38.39 |
Price Performance
Historical ComparisonAbout SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.